The US Food and Drug Administration (FDA) has approved a new colon-cleansing drug, a dual-acting stimulant and osmotic laxative, for colonoscopy preparation. A previously available, low-volume oral phospho-soda preparation was removed from the market for safety reasons.
The advantage of a small-volume solution for bowel preparation is greater patient compliance, as use of large-volume cleansing preparations may be a deterrent to some patients for having the procedure. Increased use of screening colonoscopy and cleaner bowel allowing high-quality colonoscopy may improve screening rates and cancer detection.
Study Synopsis and Perspective
The FDA has approved Prepopik, a new bowel preparation for cleansing the colon before colonoscopy.
When it becomes available, the dual-acting stimulant and osmotic laxative will be notable for its low volume, representing "the lowest volume active ingredient colon preparation available — with 10 ounces of prep solution," according to a news release.
The preparation consists of 2 packets of sodium picosulfate, magnesium oxide, and citric acid. In a split-dose regimen, patients dissolve the first packet of powder into water and drink the orange-flavored solution the night before a scheduled colonoscopy, and then do the same for the second packet the morning of the procedure.
If that split-dose regimen cannot be performed, patients may also take the drug as a day-before regimen in the afternoon and evening before a colonoscopy.
Patients are also advised to drink additional fluids during and after use of the preparation to reduce the risk for fluid and electrolyte imbalance.